异他司特治疗相关疾病的疗效。
Efficacy of Istradefylline for the Treatment of -Related Disease.
作者信息
Miyamoto Ryosuke, Kawarai Toshitaka, Takeuchi Toshiaki, Izumi Yuishin, Goto Satoshi, Kaji Ryuji
机构信息
Department of Neurology Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
Department of Rehabilitation National Hospital Organization Utano Hospital Kyoto Japan.
出版信息
Mov Disord Clin Pract. 2020 Sep 7;7(7):852-853. doi: 10.1002/mdc3.13067. eCollection 2020 Oct.
Abstract
View Supplementary Video 1 View Supplementary Video 2.
摘要
查看补充视频1 查看补充视频2。
相似文献
1
Efficacy of Istradefylline for the Treatment of -Related Disease.异他司特治疗相关疾病的疗效。
Mov Disord Clin Pract. 2020 Sep 7;7(7):852-853. doi: 10.1002/mdc3.13067. eCollection 2020 Oct.
2
The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.腺苷A2A受体拮抗剂异他林可增强低剂量多巴胺激动剂对MPTP处理的普通狨猴的抗帕金森病活性。
Eur J Pharmacol. 2015 Jan 15;747:160-5. doi: 10.1016/j.ejphar.2014.11.038. Epub 2014 Dec 11.
3
The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.腺苷A2A受体拮抗剂异他必利可增强低剂量左旋多巴和多巴胺激动剂联合治疗对MPTP处理的普通狨猴诱导的抗帕金森病活性。
Eur J Pharmacol. 2015 Nov 5;766:25-30. doi: 10.1016/j.ejphar.2015.09.028. Epub 2015 Sep 28.
4
Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.腺苷拮抗剂伊曲茶碱治疗帕金森病的适宜性：药代动力学和临床考虑。
Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):1015-24. doi: 10.1517/17425255.2013.795541. Epub 2013 May 6.
5
Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).腺苷A2A受体拮抗剂依曲茶碱（KW-6002）可减少帕金森病的“关”期：一项双盲、随机、多中心临床试验（6002-US-005）。
Ann Neurol. 2008 Mar;63(3):295-302. doi: 10.1002/ana.21315.
6
Efficacy of Caffeine in ADCY5-Related Dyskinesia: A Retrospective Study.ADCY5 相关运动障碍中咖啡因的疗效：一项回顾性研究。
Mov Disord. 2022 Jun;37(6):1294-1298. doi: 10.1002/mds.29006. Epub 2022 Apr 5.
7
Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.腺苷A2A受体拮抗剂异他司林作为帕金森病增效治疗的疗效：一项随机对照试验的荟萃分析
Cell Biochem Biophys. 2015 Jan;71(1):57-62. doi: 10.1007/s12013-014-0162-7.
8
Sleep in -Related Dyskinesia: Prolonged Awakenings Caused by Abnormal Movements.睡眠相关运动障碍：异常运动导致的长时间觉醒。
J Clin Sleep Med. 2019 Jul 15;15(7):1021-1029. doi: 10.5664/jcsm.7886.
9
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.腺苷A(2A)受体拮抗剂异他司林治疗晚期帕金森病的随机试验。
Neurology. 2003 Aug 12;61(3):297-303. doi: 10.1212/01.wnl.0000081227.84197.0b.
10
Adenosine A₂A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets.腺苷 A₂A 受体拮抗剂伊曲茶碱增强了 MPTP 处理的普通狨猴的 L-DOPA 运动反应，而不会加重运动障碍。
J Pharmacol Sci. 2014;124(4):480-5. doi: 10.1254/jphs.13250fp. Epub 2014 Mar 28.
引用本文的文献
1
Scoping Review on ADCY5-Related Movement Disorders.关于腺苷酸环化酶5相关运动障碍的范围综述
Mov Disord Clin Pract. 2023 Jun 6;10(7):1048-1059. doi: 10.1002/mdc3.13796. eCollection 2023 Jul.
2
Improvement of -Related Dyskinesias with Coffee.咖啡改善与……相关的运动障碍。 （注：原文中“-Related”部分内容缺失，这里是按现有内容翻译）
Mov Disord Clin Pract. 2022 Nov 24;10(2):329-330. doi: 10.1002/mdc3.13610. eCollection 2023 Feb.
3
Effects of theophylline on ADCY5 activation-From cellular studies to improved therapeutic options for ADCY5-related dyskinesia patients.茶碱对 ADCY5 激活的影响——从细胞研究到改善 ADCY5 相关运动障碍患者的治疗选择。
PLoS One. 2023 Mar 3;18(3):e0282593. doi: 10.1371/journal.pone.0282593. eCollection 2023.
4
Identification of hub genes and functional modules in colon adenocarcinoma based on public databases by bioinformatics analysis.基于公共数据库通过生物信息学分析鉴定结肠腺癌中的枢纽基因和功能模块。
J Gastrointest Oncol. 2021 Aug;12(4):1613-1624. doi: 10.21037/jgo-21-415.
本文引用的文献
1
ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder.腺苷酸环化酶5相关运动障碍：改善对一种不断演变疾病的临床检测
Mov Disord Clin Pract. 2019 Aug 19;6(7):512-520. doi: 10.1002/mdc3.12816. eCollection 2019 Sep.
2
Methylphenidate Can Improve Chorea in and Mutation-positive Patients-A Report of Two Children.哌甲酯可改善亨廷顿舞蹈症基因和Tourette综合征基因突变阳性患者的舞蹈症——两名儿童的报告
Mov Disord Clin Pract. 2018 Apr 6;5(3):343-345. doi: 10.1002/mdc3.12608. eCollection 2018 May-Jun.
3
Striatal Gα/cAMP Signal-Dependent Mechanism to Generate Levodopa-Induced Dyskinesia in Parkinson's Disease.纹状体Gα/环磷酸腺苷信号依赖机制在帕金森病中产生左旋多巴诱导的异动症。
Front Cell Neurosci. 2017 Nov 21;11:364. doi: 10.3389/fncel.2017.00364. eCollection 2017.
4
Abnormal striatal plasticity in a DYT11/SGCE myoclonus dystonia mouse model is reversed by adenosine A2A receptor inhibition.DYT11/SGCE 肌阵挛性肌张力障碍小鼠模型纹状体异常可塑性可被腺苷 A2A 受体抑制所逆转。
Neurobiol Dis. 2017 Dec;108:128-139. doi: 10.1016/j.nbd.2017.08.007. Epub 2017 Aug 18.
5
Phenotypic insights into ADCY5-associated disease.对ADCY5相关疾病的表型见解。
Mov Disord. 2016 Jul;31(7):1033-40. doi: 10.1002/mds.26598. Epub 2016 Apr 8.
6
Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease.腺苷A2A受体拮抗剂作为帕金森病对症治疗的作用机制。
Int Rev Neurobiol. 2014;119:87-116. doi: 10.1016/B978-0-12-801022-8.00004-0.
7
Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia.腺苷 A2A 受体拮抗作用可挽救 DYT1 型肌张力障碍模型中的多巴胺 D2 受体功能障碍。
Neurobiol Dis. 2010 Jun;38(3):434-45. doi: 10.1016/j.nbd.2010.03.003. Epub 2010 Mar 19.
Zotero 插件